IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

:

Takashi GOTO et al.

Attn: BOX PCT

Serial No. NEW

Docket No. 2000-0578A

Filed May 4, 2000

HEPARIN COFACTOR II PREPARATION AND PROCESS THEREFOR [Corresponding to PCT/JP98/04939 Filed October 30, 1998]

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of (X) the references listed on the attached Form PTO-1449 and/or () the additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in International No. <u>PCT/JP98/04939</u>.

- 1. This Information Disclosure Statement is submitted:
 - a. () within 3 months of the filing date of the above-identified application, or (X) within 3 months of entry into National stage prosecution of an International application, or () before the mailing date of the first Office Action on the merits, and thus:
 - (X) no certification and/or fee is required.
 - b. () after the events of above paragraph 1a and prior to the mailing date of a final Office Action or Notice of Allowance, and thus:
 - () the certification of paragraph 2 below is provided, or

a fee of \$240.00 is enclosed. () after the mailing date of a final Office Action or a Notice of Allowance and () C. prior to payment of the issue fee, and thus: the certification of paragraph 2 below is provided, () and a Petition and fee of \$130.00 are enclosed. () It is hereby certified 2. that each item of information contained in this Information Disclosure Statement () was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or that no item of information contained in the Information Disclosure Statement was () cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement. Consideration of the following additional information (including any co-pending or 3. 0 abandoned U.S. application, prior uses and/or sales, etc.) is requested: For each non-English language reference listed on the attached Form PTO-1449: 4. ()reference is made to an English language translation submitted herewith, 0 and/or reference is made to a foreign patent office search report (in the English 0 language) submitted herewith, and/or reference is made to an English language translation of a foreign patent 0 office search report submitted herewith, and/or reference is made to the concise explanation contained in the specification 0 of the present application at page(s), and/or reference is made to the concise explanation set forth below: 0 - 2 -

Applicant also offers the following comments for the Examiner's consideration: 5. 0

The cited references are those from the International Search Report, submitted herewith (Attachment). It is believed that WIPO has provided copies of these references to the PTO.

Also enclosed is a copy of the International Search Report citing these references, 6. Written Opinion with English translation and Applicants' Response with English translation.

Respectfully submitted,

Takashi GOTO et al.

By Warren M. Cheek, Sr. Registration No. 33,367

Attorney for Applicants

WMC/dlk Washington, D.C. Telephone (202) 721-8200 Facsimile (202) 721-8250 May 4, 2000

Sheet 1 of 1								09/5	30	702		
FORM PTO 1449 (m	odified)		ATTY DOCKET NO.			SERIAL	NO.					
U.S. DEPARTMENT OF COMMERCE				2000-0578A			NEW					
LIST OF REFERENCES CITED BY APPLICANT(S)				APPLICANT Takashi GOTO) et al. 42	22 Rec	'd PC	CT/PTO	04	MAY	2000	
(Use several sheets if necessary)				FILING DATE			GROUP					
Date Submitted to PTO: May 4, 2000				May 4, 2000						· · · · ·		
				U.S. PATENT DO		T				50,000	A TE 15	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAM	E	CLASS		SUBCLASS		FILING DATE IF APPROPRIATE		
	AA	5,219,995	6/93									
	AB						·					
	AC		d din i						_ _			
	AD											
	AE											
	AF											
	AG											
	АН											
	Al											
				FOREIGN PATENT I	OCUMENTS	T		1				
		DOCUMENT NUMBER	DATE	COUN	TRY	CL	ASS	SUBCLASS		TRANSLATION YES NO		
	AJ	2-167232	6/90	Ji	•	-						
	AK	3-128398	5/91	JI	· · · · · · · · · · · · · · · · · · ·							
	AL	416983	3/91	El								
	АМ	496725	7/92	EI	.							
	AN	9-286797	11/97	JI	>							
	S) (Including Author	, Title, Date, Pe	rtinent Pag	ges, Etc.)								
	AO	P. Toulon et al., "Purification of heparin cofactor II from human plasma" J. Chromatogr., 1991, Vol. 539, No. 2, pp. 493-500, refer to abstract, Purification of HCII, Table I.										
	AP	E. Petzelbauer et al., "Modulation of heparin cofactor II activity by glycosaminoglycans and adhesive glycoproteins", Thromb. Res., 1992, Vol. 66, pp. 559-567, refer to abstract, materials and methods, Fig. 1.										
	AQ	R. Yamagishi et al., "Purification and biological property of heparin cofactor II: activation of heparin cofactor II: activation of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminolycans", Thromb. Res., 1984, Vol. 36, pp. 633-642, materials and methods (Purification of HCII), refer to Table 1.										
EXAMINER					DATE CONSIDERED							

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.